Abstract Details

Title Age-specific Differences in the Use of Endovascular Treatment and Hospital Outcomes in Patients with Acute Ischemic Stroke: A Community-wide Perspective

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S20 - Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy (5:06 PM-5:18 PM)

Poster/Presentation
Number 009

Objective We performed this analysis to evaluate trends in the utilization of endovascular treatment in acute ischemic stroke by age strata in real-world practice.

Background Relatively limited information is available about trends over time in the use of endovascular treatment in patients of different ages hospitalized with acute ischemic stroke and the association between use of thrombectomy treatment and hospital outcomes in age strata.

Design/Methods We conducted this study by identifying patients admitted with a primary diagnosis of ischemic stroke in the United States from 2007 to 2016 using the Nationwide Inpatient Sample. International Classification of Diseases, ninth revision, and tenth, Clinical Modification (ICD-9-CM), ICD-10-CM codes were used to identify patients admitted for ischemic stroke and undergoing endovascular treatment.

Results Of the 4,590,533 patients admitted with ischemic stroke, 269,922 (5.88%) received intravenous thrombolytic treatment, and 51,375 (1.12%) underwent endovascular treatment. There is almost 12 fold significant increase in the use of endovascular treatment patients admitted with acute ischemic stroke between 2007 to 2016. Patients who were 75 years and older experienced a marked increase in the receipt of endovascular treatment over time. (0.12% 2007; 1.91% 2016). Use of endovascular treatment was associated with reduced hospital mortality in each of the four agespecific groups under study (<55, 55-64, 65-74, > or =75years). We observed statistically significant improvement in functional outcomes in all age groups.

Conclusions Our findings indicate a recent increase in the use of endovascular in middle-aged and elderly patients with acute ischemic strokes. The impact of endovascular treatment on hospital outcomes was observed in each of our age strata understudy though the magnitude of absolute and relative benefit varied according to age.

Authors/Disclosures
PRESENTER	No disclosure on file
Saqib A. Chaudhry, MD	Dr. Chaudhry has nothing to disclose.
	No disclosure on file
Ameer Hassan, DO (Valley Baptist Medical Center)	Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Stryker. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Penumbra. Dr. Hassan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare.
Sairah Bashir, MD, FAAN	Dr. Bashir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic .
	No disclosure on file
Farhan Siddiq, MD	Dr. Siddiq has nothing to disclose.
Muhammad F. Suri, MD (St Cloud Hospital)	Dr. Suri has nothing to disclose.
Camilo R. Gomez, MD, FAAN (University of Missouri)	Dr. Gomez has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.

��ɫ��

��ɫ��